




## Humana Physician News

**Q2 2024 newsletter** for in-network physicians, clinicians and office staff to support you in the care of your Humana-covered patients



### Now available from Humana

#### NEW! 2024 preauthorization lists (PAL) and notification requirements

Lists of services and medications, effective July 1, 2024, that may require preauthorization for patients with Medicare Advantage, Medicaid, dual Medicare-Medicaid and commercial coverage are now available.

[Review PAL →](#)

#### Medical and Pharmacy Coverage Policies

Humana's Medical and Pharmacy Coverage Policies for Medicare are available. Access the most current versions of coverage policies and other helpful information below.

[Access coverage policies →](#)

#### NEW! 2024 provider manuals


Humana Medicare and Medicaid provider manuals, effective March 15, 2024, are now available.\*

[Access provider manuals →](#)

#### Quality and Stars learning series

Humana provides educational webinars each month, covering Quality and Stars-related topics for both learning purposes and continuing education credits.

[Register for summer webinars →](#)



### Increasing medication adherence in seniors


A recent **Humana Healthcare Research study** revealed a correlation between medication adherence and newly diagnosed cognitive decline disorders.<sup>1</sup> Compared to those who missed no measures, risk for newly diagnosed cognitive decline **increased** as follows:

Number of missed measures	Percent increase of risk		
	Any cognitive decline	Alzheimer's	Dementia
1	23%	27%	33%
2-3	37%	96%	58%
4+	64%	148%	105%

These results may help providers promote adherence by giving patients additional reasons to take their medication regularly. Also, if costs are a concern, there are many resources (e.g., patient assistance programs, grants and insulin savings programs) available if patients meet qualification criteria.

[Review patient resources →](#)

### Utilization Management



#### DID YOU KNOW? Peer-to-peer conversations

Peer-to-peer (P2P) conversations help ensure that a patient receives appropriate and medically necessary services. But there are also provider benefits, including multidisciplinary collaboration, enhanced quality of care and reduced risk.

Most Humana denials result from incomplete information about the specific requested service and/or missing clinical information. However, before any adverse prior authorization determination is made, a conversation between the physician ordering the services and a board-certified, licensed Humana medical director is offered. These P2P conversations are intended to provide an opportunity to discuss the services being requested for the patient and the clinical rationale for this treatment.

[Read the P2P flyer →](#)

[Read the P2P booklet →](#)




### Now available: continuous glucose monitoring supplies at the pharmacy

Studies show that the use of continuous glucose monitoring (CGM) supplies improve glycemic control.<sup>2</sup> CGMs for Humana Medicare Advantage patients are now available at retail and mail-order pharmacies. Effective Jan. 1, 2024, CenterWell Pharmacy® offers durable medical equipment for diabetic products and offers certain meters and their test strips and lancets at a \$0 cost share.

[Learn what's covered →](#)

## Resources and support




#### Virtual health classes for seniors

The Humana Neighborhood Center® offers a variety of online health and well-being programs to help seniors better manage chronic conditions, maintain fitness, learn healthy recipes, connect with others and more.

**Available at no additional cost, regardless of insurance coverage**, physicians and care teams can encourage patients to take advantage of an array of classes or schedule a one-on-one visit with a health educator online.


[Review provider resources →](#)



#### Simplify the way you close care gaps

The Clinical Quality Validation (CQV) tool is a time-saving app on **Availity Essentials™** that simplifies the way practices can close care opportunities. In one digital work queue, you can manage requests and exchange information directly with Humana and other participating health plans.

[Learn about the CQV tool →](#)



#### Reduce heart failure-related hospitalizations with quadruple drug therapy

The American Heart Association recommends quadruple drug therapy (RASi/ARNi, MRA, BB, SGLT-2i) for managing heart failure with reduced ejection fraction (HFrEF) patients, which is shown to reduce cardiovascular mortality and heart failure hospitalizations **by up to 64%**.<sup>3,4</sup> Only 5% of Humana HFrEF members are currently on quadruple drug therapy, demonstrating an opportunity to increase medication adherence to improve patient outcomes.<sup>5</sup> Please review the guidelines and consider prescribing quadruple drug therapy, as appropriate.

[Review guidelines →](#)

### Additional links


- [Preauthorization and notification lists →](#)
- [Making It Easier: Series about doing business with us →](#)
- [Important policy reminders →](#)
- [Clinical practice guidelines →](#)
- [Claims payment policies →](#)
- [Behavioral health credentialing and resources →](#)
- [Claims processing edits →](#)
- [Medical and Pharmacy Coverage Policies →](#)
- [Medicare/Medicaid annual compliance training →](#)
- [Moving to value-based care →](#)

### Connect with us



[Subscribe to Humana Physician News](#)

[Humana.com/Provider](#)



[Legal](#) | [Privacy Practices](#) | [Internet Privacy Statement](#)

#### References

- Patrick N. Racsa et al., "Association of medication adherence quality measures for diabetes, hypertension, and hyperlipidemia with cognitive decline," *Journal of Family Medicine and Primary Care* 12, no. 11 (November 2023): 2667–2675, accessed March 25, 2024, [doi: 10.4103/jfmpc.jfmpc\\_935\\_23](#).
- Medha N. Munshi, "Continuous Glucose Monitoring Use in Older Adults for Optimal Diabetes Management," *Diabetes Technology & Therapeutics* 25, no. S3 (June 2023): S-56-S-64, accessed March 25, 2024, [doi: 10.1089/dia.2023.0111](#).
- Paul A. Heidenreich et al., "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines," *Circulation* 145, no. 18 (April 2022): e895–e1032, accessed March 25, 2024, [doi:10.1161/CIR.0000000000001063](#).
- Jasper Tromp et al., "A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction," *JACC: Heart Failure* 10, no. 2 (February 2022): 73–84, accessed March 25, 2024, [doi:10.1016/j.jchf.2021.09.004](#).
- Humana Internal Analytics data, 2023.

\* While many are available now, others will be posted throughout the year. This is an automated email notification and is unable to receive replies. If you do not want us to contact you by email, you can [unsubscribe](#) from our online community. Confidential and proprietary information. For provider use only. Do not distribute. All product names, logos, brands and trademarks are property of their respective owners, and any use does not imply endorsement.

Humana  
500 W. Main St.  
Louisville, KY 40202  
439205ALLO324  
GHHM99NEN